Chemotherapy: Single Drug and Combination Treatments

Chemotherapy is the use of drugs to kill cancer cells and shrink tumors. Chemotherapy is a well-established and widely used treatment for all cancers and most of us probably know someone who has undergone "chemo". It follows, then, that most of us also know that chemotherapy has serious side effects.

The side effects are largely due to the fact that, because chemotherapy is applied to the whole body (a "systemic" treatment), it not only destroys cancer cells in a specific location but harms many normal, noncancerous cells as well. Chemotherapy drugs are engineered to attack cells that divide rapidly. They do a good job of attacking metastasizing cancer cells but also damage rapidly dividing cells such as red and white blood cells, platelets, cells in the digestive lining and, as you might guess, hair follicles.

Many advances have been made (and are still underway) in chemotherapy over the years, and more and more drugs are becoming available to target specific kinds of cancer cells and to minimize side effects.

Undergoing "chemo," however, is still a difficult process for the patient. But for lymphoma patients--especially non-Hodgkin lymphoma patients--chemotherapy is often an essential treatment because the disease often spreads throughout the body.

Chemotherapy treatments for lymphomas vary widely depending on the patient and the stage of the disease. Drugs may be taken by pill, or administered via injection. A lymphoma patient may take only a single drug or undergo a regimen involving a combination of drugs.

Two types of drug agents are routinely used for chemotherapy: alkylating agents and nucleosides:

Alkylating Agent: A cytotoxic (toxic to cells) agent that inhibits cell division by reacting with DNA.
Nucleosides: These inhibit DNA and RNA replication and thereby prevent cancer cells from growing.

These are no longer the only options as researchers continue to develop new drugs. In fact, there are countless possible treatment regimens because drugs are frequently used in combination. With so many variables it is very important to get second or even third opinions regarding the type and stage of your lymphoma and the recommended treatment.

Here we list some of the more prevalent treatments. The type of treatment depends on the patient and on the type and stage of lymphoma. Multiple treatments might also be necessary for some patients. This is by no means comprehensive and is only intended to present a broad outline.

Single Drug Treatments (usually for slow-developing NHL)

  • Fludarabine
  • Cladribine
  • Chlorambucil (Leukeran®)
  • Cyclophosphamide (Neosar®)

Combination Treatments

CHOP: cyclophosphamide (Neosar®), hydroxydaunomycin, vincristine (Oncovin®), prednisone

CVP: cyclophosphamide, vincristine and the steroid prednisone - often given with rituximab (Mabthera®)

BACOD: bleomycin, doxorubicin (Adriamycin®), cyclophosphamide (Neosar®), vincristine (Oncovin®), dexamethasone

DHAP: dexamethasone, cytarabine, cisplatin - sometimes given with rituximab (Mabthera®)

EPOCH: etoposide, prednisone, vincristine (Oncovin®), cyclophosphamide (Neosar®), fluoxymesterone (Halotestin®)

ESHAP: etoposide, methylprednisolone, cytarabine and cisplatin - sometimes given with rituximab (Mabthera®)

FAD: fludarabine, doxorubicin, and the steroid dexamethasone

FMD: fludarabine, mitoxantrone and dexamethasone

ICE: ifosfamide, carboplatin, and etoposide - often given with rituximab (Mabthera®)

MACOP-B: methotrexate, doxorubicin (Adriamycin®), cyclophosphamide, vincristine (Oncovin®), prednisone, bleomycin

PMitCEBO: prednisolone, mitoxantrone, cyclophosphamide, etoposide, bleomycin and vincristine

Pro-MACE-CytaBOM: prednisone, methotrexate (with leucovorin rescue), doxorubicin (Adriamycin®), cyclophosphamide (Neosar®), etoposide, cytarabine, bleomycin, vincristine (Oncovin®)

Side Effects of Chemotherapy

Chemotherapy is tough on the body. The drugs attack the entire body and this can produce a variety of complications. Common side effects include nausea and vomiting, diarrhea, hair loss, weight loss, Depression, mouth sores, leukopenia (decreased white blood cell count; may lower resistance to infection)

Most of the above side effects are temporary and usually (though not always) not too serious. Potentially serious side effects may include neutropenia (a severe drop in white blood cells), anemia (decreased red blood cell count), peripheral neuropathy (nerve damage), liver and kidney damage, thrombocytopenia (abnormal blood clotting), allergic reaction, and tumor lysis syndrome (specific to bulky lymphomas–cells split apart and release fragments into the bloodstream).

Alternatives to Chemotherapy

Chemotherapy is not always the best option for all lymphomas, and new treatments are emerging. Follow the links below for more information.

Related Reading

General Chemotherapy Info

Catheters

Drug Information

Side Effects

Non-Hodgkin's Lymphoma Information Pages:

Photo: Pexels

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap